LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Researchers Develop World’s First AI-Augmented Ova and Parasite Detection Tool

By LabMedica International staff writers
Posted on 29 Aug 2019
Image: ARUP Laboratories and Techcyte have developed the world’s first AI-augmented ova and parasite detection tool (Photo courtesy of Techcyte).
Image: ARUP Laboratories and Techcyte have developed the world’s first AI-augmented ova and parasite detection tool (Photo courtesy of Techcyte).
ARUP Laboratories (Salt Lake City, UT, USA), a national reference laboratory engaged in innovative laboratory research and development, and Techcyte (Lindon, UT, USA), a developer of artificial intelligence (AI) based image analysis solutions for the diagnostics industry, have developed the world’s first AI-augmented ova and parasite detection tool.

ARUP, a national clinical and anatomic pathology reference laboratory, is a non-profit enterprise of the University of Utah and offers an extensive test menu of highly complex and unique medical tests. Techcyte, which was founded as a technology transfer from the University of Utah, uses the power of deep machine learning to perform image analysis of whole slide images. Techcyte’s digital diagnostics platform applies the latest in convolutional neural networks to pre-classify the fecal sample images captured by a 3DHISTECH Pannoramic 250-Flash III scanner. Pre-classifying the images using the Techcyte tool allows ARUP’s technologists to efficiently read stained glass slides manually and improves the accuracy of parasite detection.

For laboratorians, digitally enabling the workflow will decrease the physical demands of looking through a microscope for extended periods of time, including eye fatigue and neuromuscular tension. The technology can quickly screen out negative results, allowing laboratorians to spend more time analyzing positive slides. The ova and parasite tool is the first among several projects being co-developed by ARUP and Techcyte. ARUP’s medical expertise and access to samples, combined with Techcyte’s technical ability and digital evaluation platform, will produce high quality algorithms that can be developed and applied to future unmet laboratory needs.

“The collaboration with Techcyte has produced an AI-augmented detection tool that significantly advances our diagnostic capabilities in our parasitology lab,” said Adam Barker, PhD, director of Research and Development at ARUP. “This will allow for faster turnaround times, decreased costs, employee satisfaction and improved patient care.”

“Microscopy-based diagnostic parasitology has remained woefully static for decades. We have successfully developed a pioneering breakthrough with this tool, the likes of which had previously been unimaginable by classically trained microbiologists,” said Dr. Marc Couturier, medical director of ARUP’s Parasitology labs.

“This revolutionary partnership will combine ARUP’s vast expertise and reputation in the market with Techcyte’s AI-based image analysis capabilities to change the way lab diagnostics are performed,” said Ralph Yarro, CEO of Techcyte.

Related Links:
ARUP Laboratories
Techcyte

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more